Brief: Precigen Receives FDA Clearance Of Ind To Initiate Phase 2 Study Of Prgn-2009 Off-The-Shelf Adenoverse Immunotherapy In Combination With Pembrolizumab To Treat Patients With Recurrent Or Metastatic Cervical Cancer

Precigen

31/05/2023 13:08

May 31 (Reuters) - Precigen Inc  PGEN.O :
    * PRECIGEN RECEIVES FDA CLEARANCE OF IND TO INITIATE PHASE 2
STUDY
OF PRGN-2009 OFF-THE-SHELF ADENOVERSE IMMUNOTHERAPY IN
COMBINATION WITH PEMBROLIZUMAB TO TREAT PATIENTS WITH RECURRENT
OR METASTATIC CERVICAL CANCER

Source text for Eikon:  ID:nPn5t0dy8a 
Further company coverage:  PGEN.O 

 ((Reuters.Briefs@thomsonreuters.com;))